Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Savara a “Moderate Buy” consensus: Six analysts rate the stock a buy, one rates it a strong buy, and one recommends selling. The average 12-month price target is $10.14, versus a recent price of $5.59.
• Institutional ownership is high at 87.93%: Several investment firms increased their stakes, while Nan Fung Trinity and OrbiMed Advisors initiated new positions.
• Savara reported a quarterly loss of $0.16 per share, missing expectations by $0.02. The clinical-stage biotech is advancing Molgradex, its lead treatment for autoimmune pulmonary alveolar proteinosis, through regulatory review.

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.1429.

A number of equities research analysts have issued reports on the company. Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th.

Savara Price Performance

Savara stock opened at $5.59 on Monday. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. Savara has a 52-week low of $2.98 and a 52-week high of $7.01. The firm has a market cap of $1.15 billion, a PE ratio of -9.64 and a beta of 0.29. The company's 50 day moving average is $5.69 and its two-hundred day moving average is $5.48.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, research analysts expect that Savara will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Swedbank AB lifted its holdings in Savara by 54.5% during the 4th quarter. Swedbank AB now owns 850,000 shares of the company's stock worth $5,126,000 after buying an additional 300,000 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Savara by 96.5% in the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company's stock valued at $3,564,000 after acquiring an additional 320,572 shares during the last quarter. F m Investments LLC raised its position in shares of Savara by 56.5% during the 4th quarter. F m Investments LLC now owns 678,813 shares of the company's stock worth $4,093,000 after acquiring an additional 245,100 shares in the last quarter. Nan Fung Trinity HK Ltd. acquired a new stake in shares of Savara during the 4th quarter worth about $10,182,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Savara during the 1st quarter worth about $3,467,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source